EISAI TO PRESENT LECANEMAB REAL-WORLD EXPERIENCE DATA AND FINDINGS FROM NEUROLOGY PORTFOLIO AT THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING [Yahoo! Finance]
DHI Group, Inc. (DHX)
Last dhi group, inc. earnings: 2/5 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
dhigroupinc.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
portfolio, including data on real-world experience and continued maintenance dosing with our dual-acting, anti-amyloid beta (Aß) protofibril* antibody for the treatment of Alzheimer's disease (AD), lecanemab (generic name, U.S. brand name: LEQEMBI ® ) at the American Academy of Neurology (AAN) Annual Meeting, being held in San Diego, California , and virtually from April 5-9 . Eisai will present two (2) oral presentations and seven (7) posters on lecanemab and the insomnia dual orexin receptor antagonist DAYVIGO ® (lemborexant) CIV. Lecanemab Real World Experience Presentations On Wednesday, April 9 , as part of Poster Session P12, "Aging, Dementia, and Behavioral Neurology: Alzheimer's Treatment" ( 11:45 AM - 12:45 PM PT ), two posters will be presented on real-world experience with lecanemab, including results on efficacy and safety in the clinical setting and patient satisfaction with their treatment experience: Real-World Experience with Long-term Lecanemab Treatment: A Retros
Show less
Read more
Impact Snapshot
Event Time:
DHX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DHX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DHX alerts
High impacting DHI Group, Inc. news events
Weekly update
A roundup of the hottest topics
DHX
News
- FDA Announcements Spark Vigorous Debate, Controversy [Forbes]Forbes
- DHI Group (NYSE:DHX) had its "hold" rating reaffirmed by analysts at Lake Street Capital. They now have a $2.50 price target on the stock, down previously from $3.00.MarketBeat
- DHI Group Inc (DHX) Q3 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... [Yahoo! Finance]Yahoo! Finance
- DHI Group, Inc. (DHX) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- DHI Group Reports Third Quarter Financial Results; Raises Full Year Profitability Guidance While Reaffirming Revenue TargetBusiness Wire
DHX
Earnings
- 11/10/25 - Beat
DHX
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/10/25 - Form 10-Q
- 11/10/25 - Form 8-K
- DHX's page on the SEC website